A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
SAN ANTONIO -- Addition of an investigational AKT inhibitor to standard fulvestrant (Faslodex) doubled median progression-free survival (PFS) in the second-line setting for patients with hormone ...
Data demonstrate that ATV-1601, a selective allosteric inhibitor of AKT1 E17K, provides enhanced target inhibition, superior efficacy and improved tolerability compared to pan-AKT inhibitors in ...
Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719. This is an ...
In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This ...
NB: this presentation will be the subject of an embargoed news briefing by co-author Dr Kevin Kalinsky on Monday 24 October at 17.00 hrs CEST. Barcelona, Spain: In a trial matching new treatments to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback